Keller Rohrback L.L.P. Announces Investigation of Pfizer, Inc. Regarding the Lo/Ovral®-28 and Norgestrel Birth Control Pil

SEATTLE--(BUSINESS WIRE)-- Attorney Advertising. Keller Rohrback L.L.P. ( is investigating possible consumer claims against Pfizer, Inc. (NYSE: PFE) relating to its recent recall of certain lots of Lo/Ovral®-28 and Norgestrel birth control pills that were sold in the U.S. This investigation focuses on the expenses incurred by consumers as a result of the recalled birth control pills, such as the cost of the pills, back-up methods of birth control, pregnancy tests, and/or consultations with a physician, as recommended by Pfizer, due to this recall.

On January 31, 2012, Pfizer voluntarily recalled approximately 1 million packets of the Lo/Ovral®-28 Tablets (norgestrel and ethinyl estradiol) and the Norgestrel and Ethinyl Estradiol Tablets (generic). The packets of birth control pills typically have 21 tablets that contain active ingredients and seven tablets of inert ingredients or “placebo” pills. However, the recalled birth control packs may contain the wrong number of each type of tablet and the tablets may be out of sequence. According to a Pfizer news release, “As a result of this packaging error, the daily regimen for these oral contraceptives may be incorrect and could leave women without adequate contraception, and at risk for unintended pregnancy.” Pfizer recommends that women who have used Lo/Ovral®-28 or Norgestrel pills over the last several months should consult with their doctor and begin using a non-hormonal birth control method immediately.

If you were prescribed Lo/Ovral®-28 or Norgestrel birth control pills that are the subject of the recall and paid money as a result, or if you would like more information regarding our investigation, please contact paralegal Maggie Norton or attorneys Havila Unrein, Sharon Hritz or Gretchen Freeman Cappio at (800) 776-6044 or via email at [email protected].

Keller Rohrback, with offices in Seattle, Phoenix, New York and Santa Barbara, is proud to offer its expertise in consumer cases to clients nationwide.

Attorney Advertising. Prior Results Do Not Guarantee A Similar Outcome.


Keller Rohrback L.L.P.
Havila Unrein or Gretchen Freeman Cappio, 800-776-6044
[email protected]

KEYWORDS:   United States  North America  Washington

INDUSTRY KEYWORDS:   Women  Health  Pharmaceutical  Professional Services  Legal  Consumer


Suggested Articles

Regeneron and Sanofi hope their PD-1 inhibitor Libtayo will be the first immuno-oncology treatment approved to treat basal cell carcinoma.

With its phase 3 trial moving right along, Moderna is expecting efficacy data in November—likely after Pfizer and BioNTech, but before everyone else.

Pfizer, GSK, BIO and others are all planning vaccine messages for fall.